HR Execs on the Move

Alucent Biomedical

www.alucentbiomedical.com

 
Alucent Biomedical, Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah and is the first company to bring a novel, locally delivered biotechnology treatment to a market traditionally dominated by medical device solutions. Alucent was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS). NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Su International

Su International is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celsius Therapeutics

Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single-cell RNA sequencing and genomic analysis to develop life-changing medicines. Our common goal is to markedly improve human health by integrating data, experience and insight. Located in Cambridge, Mass., our environment is rigorous, fast-paced and collaborative, bringing together passionate individuals who are making an impact. We inspire creativity and discovery by embracing an open culture that fosters innovation, teamwork and excellence. We are committed to attracting and retaining the best talent, and we believe that our growth and success will be driven by those who are inspired by our mission and share our values. If you`re curious, collaborative and relentless about making a difference in the lives of patients, join us!

Concerro

Concerro is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Freenome

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.

EpiVax Oncology

EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient`s unique tumor and normal genome sequence (the mutanome). EpiVax Oncology`s ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. EpiVax Oncology`s ambition is to become a premier cancer precision medicine company, leveraging EpiVax`s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.